Alexander Gerhard

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6258057/publications.pdf

Version: 2024-02-01

44 papers

3,282 citations

331538 21 h-index 254106 43 g-index

46 all docs

46 docs citations

times ranked

46

4861 citing authors

#	Article	IF	CITATIONS
1	Comparison of clinical rating scales in genetic frontotemporal dementia within the GENFI cohort. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 158-168.	0.9	7
2	Practice effects in genetic frontotemporal dementia and at-risk individuals: a GENFI study. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 336-339.	0.9	1
3	A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia. Brain, 2022, 145, 1805-1817.	3.7	27
4	Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum <scp>NfL</scp> and <scp>pNfH</scp> : A Longitudinal Multicentre Study. Annals of Neurology, 2022, 91, 33-47.	2.8	21
5	Cognitive composites for genetic frontotemporal dementia: GENFI-Cog. Alzheimer's Research and Therapy, 2022, 14, 10.	3.0	4
6	An Automated Toolbox to Predict Single Subject Atrophy in Presymptomatic Granulin Mutation Carriers. Journal of Alzheimer's Disease, 2022, , 1-14.	1.2	3
7	Structural brain splitting is a hallmark of Granulin-related frontotemporal dementia. Neurobiology of Aging, 2022, , .	1.5	1
8	Anomia is present pre-symptomatically in frontotemporal dementia due to MAPT mutations. Journal of Neurology, 2022, 269, 4322-4332.	1.8	1
9	The <scp>CBIâ€R</scp> detects early behavioural impairment in genetic frontotemporal dementia. Annals of Clinical and Translational Neurology, 2022, 9, 644-658.	1.7	1
10	Development of a sensitive trial-ready poly(GP) CSF biomarker assay for <i>C9orf72</i> -associated frontotemporal dementia and amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 761-771.	0.9	12
11	Longitudinal Cognitive Changes in Genetic Frontotemporal Dementia Within the GENFI Cohort. Neurology, 2022, 99, .	1.5	5
12	Brain functional network integrity sustains cognitive function despite atrophy in presymptomatic genetic frontotemporal dementia. Alzheimer's and Dementia, 2021, 17, 500-514.	0.4	36
13	Apathy in presymptomatic genetic frontotemporal dementia predicts cognitive decline and is driven by structural brain changes. Alzheimer's and Dementia, 2021, 17, 969-983.	0.4	31
14	Progression of Behavioral Disturbances and Neuropsychiatric Symptoms in Patients With Genetic Frontotemporal Dementia. JAMA Network Open, 2021, 4, e2030194.	2.8	42
15	Does increased microglial activation lead to faster progression in PSP?. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 685-685.	0.9	1
16	Dissemination in time and space in presymptomatic granulin mutation carriers: a GENFI spatial chronnectome study. Neurobiology of Aging, 2021, 108, 155-167.	1.5	3
17	Altered network stability in progressive supranuclear palsy. Neurobiology of Aging, 2021, 107, 109-117.	1.5	8
18	Differential early subcortical involvement in genetic FTD within the GENFI cohort. NeuroImage: Clinical, 2021, 30, 102646.	1.4	28

#	Article	IF	Citations
19	A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study. Molecular Neurodegeneration, 2021, 16, 79.	4.4	9
20	A dataâ€driven disease progression model of fluid biomarkers in genetic FTD. Alzheimer's and Dementia, 2021, 17, .	0.4	0
21	Differential synaptic marker involvement in the different genetic forms of frontotemporal dementia. Alzheimer's and Dementia, 2021, 17, .	0.4	1
22	Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Syndrome. JAMA Neurology, 2020, 77, 377.	4.5	94
23	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurology, The, 2020, 19, 145-156.	4.9	175
24	Early symptoms in symptomatic and preclinical genetic frontotemporal lobar degeneration. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 975-984.	0.9	25
25	Positron emission tomography to image cerebral neuroinflammation in ischaemic stroke: a pilot study. Efficacy and Mechanism Evaluation, 2020, 7, 1-26.	0.9	5
26	Prospects and challenges of imaging neuroinflammation beyond TSPO in Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2831-2847.	3.3	45
27	Widespread microglial activation in multiple system atrophy. Movement Disorders, 2019, 34, 564-568.	2.2	41
28	Microglial activation, white matter tract damage, and disability in MS. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e443.	3.1	51
29	Functional neuroanatomical associations of working memory in earlyâ€onset Alzheimer's disease. International Journal of Geriatric Psychiatry, 2018, 33, 176-184.	1.3	10
30	Elevated Translocator Protein in Anterior Cingulate in Major Depression and a Role for Inflammation in Suicidal Thinking: A Positron Emission Tomography Study. Biological Psychiatry, 2018, 83, 61-69.	0.7	266
31	Frontotemporal lobar degeneration and social behaviour: Dissociation between the knowledge of its consequences and its conceptual meaning. Cortex, 2017, 93, 107-118.	1.1	22
32	TSPO imaging in parkinsonian disorders. Clinical and Translational Imaging, 2016, 4, 183-190.	1.1	56
33	18F-GE-180: a novel TSPO radiotracer compared to 11C-R-PK11195 in a preclinical model of stroke. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 503-511.	3.3	109
34	[11C]-(R)PK11195 tracer kinetics in the brain of glioma patients and a comparison of two referencing approaches. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1406-1419.	3.3	55
35	Imaging of Neuroinflammation in Parkinsonian Syndromes with Positron Emission Tomography. Current Neurology and Neuroscience Reports, 2013, 13, 405.	2.0	8
36	Diffusion-weighted imaging and its relationship to microglial activation in parkinsonian syndromes. Parkinsonism and Related Disorders, 2013, 19, 527-532.	1.1	18

3

#	Article	IF	CITATIONS
37	Brain inflammation is induced by co-morbidities and risk factors for stroke. Brain, Behavior, and Immunity, 2011, 25, 1113-1122.	2.0	173
38	Minocycline 1â€year therapy in multipleâ€systemâ€atrophy: Effect on clinical symptoms and [¹¹ C] <i>(R)</i> à€PK11195 PET (MEMSAâ€trial). Movement Disorders, 2010, 25, 97-107.	2.2	163
39	Reference and target region modeling of [11C]-(R)-PK11195 brain studies. Journal of Nuclear Medicine, 2007, 48, 158-67.	2.8	216
40	In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiology of Disease, 2006, 21, 404-412.	2.1	982
41	In vivo imaging of microglial activation with [11C](R)-PK11195 PET in progressive supranuclear palsy. Movement Disorders, 2006, 21, 89-93.	2.2	162
42	Evolution of microglial activation in patients after ischemic stroke: a [11C](R)-PK11195 PET study. Neurolmage, 2005, 24, 591-595.	2.1	235
43	Correlation of regional cerebral amyloid load in Alzheimer's disease, measured with [11C]-PIB pet using spectral analysis and tissue uptake ratios, with Performance on recognition memory tests. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S591-S591.	2.4	1
44	In vivo imaging of microglial activation with [11C](R)-PK11195 PET in corticobasal degeneration. Movement Disorders, 2004, 19, 1221-1226.	2.2	128